Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Bepirovirsen via Vial vs Autoinjector in Healthy Adults
NCT07905157Phase 1Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, randomised, open-label trial of bepirovirsen in hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve from Time Zero up to Day 8 and Maximum Observed Concentration at 8 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07905157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905157.